307 related articles for article (PubMed ID: 26882224)
1. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
[TBL] [Abstract][Full Text] [Related]
2. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.
Hetta HF; Zahran AM; El-Mahdy RI; Nabil EE; Esmaeel HM; Elkady OA; Elkady A; Mohareb DA; Mahmoud Mostafa M; John J
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1927-1933. PubMed ID: 31244320
[TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
6. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
7. An approach of selecting appropriate markers from the primary tumor to enable detection of circulating tumor cells in patients with non-small cell lung cancer.
Warawdekar UM; Sirajuddin MM; Pramesh CS; Mistry RC
J BUON; 2015; 20(3):782-90. PubMed ID: 26214631
[TBL] [Abstract][Full Text] [Related]
8. Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer.
Rzechonek A; Kaminska A; Mamczur P; Drapiewski A; Budzynski W
Adv Exp Med Biol; 2017; 955():51-57. PubMed ID: 27683215
[TBL] [Abstract][Full Text] [Related]
9. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Tessema M; Yingling CM; Thomas CL; Klinge DM; Bernauer AM; Liu Y; Dacic S; Siegfried JM; Dahlberg SE; Schiller JH; Belinsky SA
Oncogene; 2012 Sep; 31(37):4107-16. PubMed ID: 22158045
[TBL] [Abstract][Full Text] [Related]
10. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.
Lui NS; van Zante A; Rosen SD; Jablons DM; Lemjabbar-Alaoui H
BMJ Open; 2012; 2(6):. PubMed ID: 23180455
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-141 is a biomarker for progression of squamous cell carcinoma and adenocarcinoma of the lung: clinical analysis of 125 patients.
Zhang X; Li P; Rong M; He R; Hou X; Xie Y; Chen G
Tohoku J Exp Med; 2015 Mar; 235(3):161-9. PubMed ID: 25746592
[TBL] [Abstract][Full Text] [Related]
12. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
[TBL] [Abstract][Full Text] [Related]
13. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
15. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
17. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
[TBL] [Abstract][Full Text] [Related]
18. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
19. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
20. Increased stathmin correlates with advanced stage and poor survival of non-small cell lung cancer.
Rong B; Nan Y; Liu H; Gao W
Cancer Biomark; 2017; 19(1):35-43. PubMed ID: 28282798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
